Fusion Antibodies plc (AIM:FAB)
London flag London · Delayed Price · Currency is GBP · Price in GBX
15.75
-1.25 (-7.35%)
Oct 3, 2025, 5:24 PM GMT+1

Fusion Antibodies Company Description

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.

The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.

It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL.

Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.

Fusion Antibodies plc
CountryUnited Kingdom
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees24
CEOAdrian Kinkaid

Contact Details

Address:
Springbank Industrial Estate
Belfast, BT17 0QL
United Kingdom
Phone44 28 9043 2800
Websitefusionantibodies.com

Stock Details

Ticker SymbolFAB
ExchangeLondon Stock Exchange AIM
Fiscal YearApril - March
Reporting CurrencyGBP
ISIN NumberGB00BDQZGK16
SIC Code8731

Key Executives

NamePosition
Adrian KinkaidChief Executive Officer
Stephen SmythChief Financial Officer
Nicola HamiltonChief Operating Officer